“The fusion of AI and healthcare is one of the most lucrative opportunities I’ve come across in my entire career,” writes the founding partner and CEO of an investment research firm.

In a pilot study of 16 patients, the system’s recommendations were deemed safe by expert endocrinologists at a clip of more than 99% over the course of four weeks.

A developer of software used in orthopedic surgery has demonstrated the utility of AI-aided fluoroscopy guidance for operating on orthopedic trauma patients.

The authors further found that a majority of hospitals are now using standalone telemedicine products rather than those that are part of their EHR.

Researchers have successfully piloted the use of augmented reality for guiding tumor ablation, completing the treatment in five patients with cancers of the liver.

Machine learning is playing a key role in predicting all major forms of drug cardiotoxicity, potentially helping reduce late-stage clinical trial failures.

Higher research and development costs are driving a need for pharmaceutical companies to leverage AI to optimize the drug discovery process––and some companies are doing so better than others.

The deal is largely focused on helping the 13-hospital institution delve deeper into various iterations of digital health, including AI.

As an academic AI expert, Pascale Fung, PhD, dove into the scientific research when she was diagnosed with breast cancer in 2015. The time investment rewarded her with a depth of understanding that has helped shape her life as a cancer survivor.

Researchers have found that spiking neural networks become unstable after unbroken periods of unsupervised self-training. Moreover, these “artificial brains” seem to restabilize after they’re given the equivalent of a good night’s rest.